Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
作者信息
Schulz Christoph, Stintzing Sebastian
机构信息
Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Department of Hematology, Oncology and Tumor Immunology (CCM) Charité - Universitaetsmedizin Berlin, Berlin, Germany.
出版信息
Transl Cancer Res. 2020 Apr;9(4):2175-2177. doi: 10.21037/tcr.2020.02.06.
Abstract
摘要
相似文献
1
Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
Transl Cancer Res. 2020 Apr;9(4):2175-2177. doi: 10.21037/tcr.2020.02.06.
2
Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
Transl Cancer Res. 2019 Sep;8(5):1656-1658. doi: 10.21037/tcr.2019.05.10.
3
HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma.
Mymensingh Med J. 2017 Apr;26(2):372-379.
4
High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
Mod Pathol. 2023 May;36(5):100154. doi: 10.1016/j.modpat.2023.100154. Epub 2023 Mar 15.
5
HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
Appl Immunohistochem Mol Morphol. 2012 Jan;20(1):13-24. doi: 10.1097/PAI.0b013e31821c821c.
6
Near infrared ray-guided surgery using Firefly technology of the daVinci Xi system and intraoperative upper gastrointestinal endoscopy for subtotal gastrectomy and surgery for cancer of the gastroesophageal junction.
BMC Surg. 2022 May 12;22(1):174. doi: 10.1186/s12893-022-01633-9.
7
A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.
Euroasian J Hepatogastroenterol. 2020 Jul-Dec;10(2):56-63. doi: 10.5005/jp-journals-10018-1321.
8
Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
Chemotherapy. 2023;68(4):197-209. doi: 10.1159/000531457. Epub 2023 Jun 16.
9
Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1139-1145. doi: 10.31557/APJCP.2019.20.4.1139.
10
Epidemiological Review of Gastroesophageal Junction Adenocarcinoma in Asian Countries.
Digestion. 2022;103(1):29-36. doi: 10.1159/000519602. Epub 2021 Oct 29.
本文引用的文献
1
Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
Transl Cancer Res. 2019 Sep;8(5):1656-1658. doi: 10.21037/tcr.2019.05.10.
2
Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer.
Cancer Chemother Pharmacol. 2019 Jun;83(6):1037-1046. doi: 10.1007/s00280-019-03817-2. Epub 2019 Mar 21.
3
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Clin Cancer Res. 2018 Mar 1;24(5):1082-1089. doi: 10.1158/1078-0432.CCR-17-2781. Epub 2017 Dec 5.
4
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49. doi: 10.1093/annonc/mdw350.
5
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Ann Oncol. 2013 Aug;24(8):2068-73. doi: 10.1093/annonc/mdt141. Epub 2013 Apr 16.
6
Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Ann Surg Oncol. 2012 Jul;19(7):2119-27. doi: 10.1245/s10434-012-2254-1. Epub 2012 Mar 7.
7
Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
J Clin Oncol. 2009 Jun 10;27(17):2863-73. doi: 10.1200/JCO.2008.19.1718. Epub 2009 Mar 30.
Zotero 插件